

The role of the gut microbiota in colorectal cancer causation

Article

Published Version

Creative Commons: Attribution 4.0 (CC-BY)

Alhinai, E. A., Walton, G. E. ORCID: <https://orcid.org/0000-0001-5426-5635> and Commane, D. M. (2019) The role of the gut microbiota in colorectal cancer causation. *International Journal of Molecular Sciences*, 20 (21). 5295. ISSN 1422-0067 doi: 10.3390/ijms20215295 Available at <https://centaur.reading.ac.uk/87360/>

It is advisable to refer to the publisher's version if you intend to cite from the work. See [Guidance on citing](#).

To link to this article DOI: <http://dx.doi.org/10.3390/ijms20215295>

Publisher: MDPI

All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in the [End User Agreement](#).

www.reading.ac.uk/centaur

CentAUR

Central Archive at the University of Reading

Reading's research outputs online



Review

The Role of the Gut Microbiota in Colorectal Cancer Causation

Eiman A. Alhinai ¹, Gemma E. Walton ^{2,*} and Daniel M. Commane ³

¹ Dietetics Department, Al Nahdha Hospital, Ministry of Health, P.O. Box 937, Ruwi, Muscat PC 112, Oman; Alhinaie78@gmail.com

² Department of Food and Nutritional Sciences, University of Reading, Reading RG6 6UA, UK

³ Department of Applied and Health Sciences, University of Northumbria, Newcastle Upon Tyne NE1 8ST, UK; Daniel.commane@northumbria.ac.uk

* Correspondence: g.e.walton@reading.ac.uk

Received: 30 September 2019; Accepted: 23 October 2019; Published: 24 October 2019



Abstract: Here, we reviewed emerging evidence on the role of the microbial community in colorectal carcinogenesis. A healthy gut microbiota promotes intestinal homeostasis and can exert anti-cancer effects; however, this microbiota also produces a variety of metabolites that are genotoxic and which can negatively influence epithelial cell behaviour. Disturbances in the normal microbial balance, known as dysbiosis, are frequently observed in colorectal cancer (CRC) patients. Microbial species linked to CRC include certain strains of *Bacteroides fragilis*, *Escherichia coli*, *Streptococcus gallolyticus*, *Enterococcus faecalis* and *Fusobacterium nucleatum*, amongst others. Whether these microbes are merely passive dwellers exploiting the tumour environment, or rather, active protagonists in the carcinogenic process is the subject of much research. The incidence of chemically-induced tumours in mice models varies, depending upon the presence or absence of these microorganisms, thus strongly suggesting influences on disease causation. Putative mechanistic explanations differentially link these strains to DNA damage, inflammation, aberrant cell behaviour and immune suppression. In the future, modulating the composition and metabolic activity of this microbial community may have a role in prevention and therapy.

Keywords: colorectal cancer; microbiota; *Fusobacteria*; *Bacteroides*; *Streptococcus Gallolyticus*; *Escherichia coli*; genotoxicity; gut

1. Introduction

The distinguishing characteristic of the colon is the relative abundance of the resident microbiota. Microbial communities present elsewhere in the GI tract are much smaller and show lower diversity. In parallel, the comparative incidence of colorectal to oesophageal and stomach cancers is approximately 30:1:2 [1,2]. Germ-free mice demonstrate the importance of host-microbe interactions to healthy host physiology; in these models, the colon architecture is visibly aberrant, there is an under-developed immune system [3], poor *wnt* signalling mediated differentiation of epithelial cells [4] and a functionally impaired epithelial barrier [5]. Further, the incidence of chemically induced tumours in mice models varies, depending upon the presence or absence of a functional microbiota [6].

Experimental intervention studies in non-germ-free animal models, with both probiotics and prebiotics, have been shown to suppress tumour development via diverse mechanisms. Several meta-analyses show that consuming a high-fibre diet reduces colorectal cancer (CRC) risk [7–9]. Fibre intake may be coupled to saccharolytic microbial activity in the gut and, in particular, the in situ synthesis of butyrate, with its well-studied anti-neoplastic activity. Thus, these strands of evidence indicate the importance of a healthy microbiota in cancer suppression. In contrast, we reviewed here the emerging evidence of the role of the microbial community in promoting colorectal carcinogenesis.

2. The Healthy Microbiota

In a healthy host, the colonic microbiome is typically dominated, at the phyla level, by Gram-negative *Bacteroidetes* and Gram-positive *Firmicutes*, with a smaller but sizable abundance of *Actinobacteria* and *Verrucomicrobia* [10,11]. The proportions of these phyla are not fixed, and different phyla, and indeed families, strains and species, compete to fulfil distinct ecological niches. Thus, under the influences of age, gender, genetics, diet and disease, there is considerable scope for inter-individual variation between phenotypically similar and healthy individuals [12]. Microbial diversity between individuals does not appear to critically influence central pathways in microbial metabolism. The fermentation of carbohydrates generally yields short-chain fatty acids, which can be used by the host, whilst proteolytic fermentation also yields phenols, cresols, ammonia and sulphides, commonly thought of as toxins. The production of specific secondary metabolites with pro and/or anti-carcinogenic activities, such as enterotoxins, cyclomodulins, B vitamins, urolithins, the estrogenic equol and mammalian lignans, may, however, be dependent on the abundance of certain strains, or functional groups, of bacteria. Equol, for example, is associated with a reduced risk of CRC [13], but is produced by fewer than 50% of the population and is dependent on colonisation with a handful of daidzein metabolising species [14].

3. The Microbiological Environment in Colorectal Cancer

Colorectal cancer has at least four recognised distinct common molecular subtypes [15]. Broadly speaking, cancers in the descending colon and rectum demonstrate high levels of chromosomal instability (CIN) and a strong up-regulation of *wnt* signalling [16]; in contrast, cancers of the ascending colon are rarer and are more likely to be of the microsatellite instability (MSI) subtype. Thus, the favoured anatomical distribution of these tumour sub-types hints at distinct aetiologies [17]. The right and left side of the colon have different embryological origins, but physiologically, these sections of the colon may be characterised as having distinct microbial activities. Saccharolytic fermentation dominates in the ascending colon, where the high fluid volume may also make the luminal contents quite dilute [18]. Microbial metabolites produced in the caecum, including short-chain fatty acids, may be reabsorbed, with water and electrolytes, in situ and through the transverse colon, such that the contents of the descending colon are more concentrated in biomass and potentially in toxic metabolites. In in vitro models, total microbial activity appears to decrease in the latter portions of the bowel and proteolysis becomes favoured [19,20]. Thus, distal and proximal colonocytes may be exposed to quite different microbial metabolites. To this point, these gradients in exposures have been poorly considered in relation to tumour subtype. Perhaps problematically, the aetiological/epidemiological studies continue to view CRC as a single disease, and therefore going forward, we will need to better consider tumour site and subtype in relation to diet and microbial exposures.

4. Microbial Metabolism in Carcinogenesis

Yachida et al. [21] compared the abundance of microbial metabolism genes present in stool between healthy controls and volunteers at different stages of the colorectal cancer process. In volunteers with preneoplastic polyps, they noted an increase in the abundance of genes involved in amino acid and sulphur metabolism and a relative decrease in the abundance of genes involved in methane metabolism. This is consistent with the long-standing assumption that a gut microbial environment favouring proteolytic over saccharolytic fermentation may increase CRC risk. With a western diet, somewhere between 6 and 18 g of protein per day is thought to reach the colon [22,23]. With decreasing availability of fermentable carbohydrate in the distal colon, there is a shift towards the production of proteolytic end products in the more cancer-prone left side [24]. In in vitro mixed culture models of gut fermentation, increasing protein concentrations in culture media leads to elevated production of phenolic compounds, amines, ammonia and hydrogen sulphide. These metabolites can be leveraged as nitrogen sources for bacterial cross-feeding, or they may be taken up by colonocytes and transported

into the bloodstream [25]; however, their accumulation in the colonic lumen is associated with increased epithelial cell toxicity [26,27].

The amino acid composition of the protein substrate influences the overall composition of this potentially genotoxic fermentation supernatant. For example, methionine and cysteine may be used as a substrate by the sulphate-reducing bacteria (SRB) (i.e., *Desulfovibrio*, *Desulfotomaculum*, *Desulfobacter*, *Desulfobulbus* [28]), leading to the generation of H₂S [28,29]. Hydrogen sulphide inhibits butyric acid oxidation [30–32], it increases cell proliferation in vitro [33] and is shown to be genotoxic [34]. In in vitro batch-culture fermentation with faecal inoculate, the rate of H₂S production differs according to whether albumin or casein is used as a substrate [35]. In human observational studies, the sulphate reducing bacteria may be associated with inflammatory bowel disease [36] and are putatively implicated in its pathogenesis through the ability of H₂S to compromise barrier function [29,37]. In both animal and human dietary intervention study, diets high in protein increase the recovery of sulphide in faeces [38], and Yachida et al. [21] observed an increase in the abundance of sulphate-reducing bacteria in stool samples from stage II and III cancer patients versus healthy controls.

Fermentation of aromatic amino acids leads to the production of phenols, indoles and 4-cresol. These are not well recovered in stool, but rather enter the hepatic circulation to be detoxified in the liver and eventually excreted in urine [39]. Studies have shown that with high protein intake, metabolites of 4-cresol and phenol appear in the urine [40]. Phenol and 4-cresol reach genotoxic concentrations in the in vitro gut fermentation models, which vary according to a protein source, and their concentration can be used to predict the genotoxicity of gut fermentation supernatants [41].

In contrast to the epidemiological data, the carcinogenicity of higher protein diets is consistently demonstrated, particularly in relation to colonic inflammation, in experimental animal models [42]. Higher protein dietary interventions in human volunteers lead to increased urinary excretion of markers of amino acid fermentation, but the appearance of these metabolites in urine does not necessarily correlate with increased faecal water genotoxicity [43,44]. Colonic fermentation and absorption are dynamic; therefore, faecal samples may be poorly representative of colonic exposures. Better biomarkers of cancer risk for human dietary intervention study are certainly needed to bridge the gap between the lack of associations between protein intake and cancer in human subjects versus the mechanistic and animal experimental evidence, implicating proteolytic gut fermentation metabolites in CRC.

5. The Colon Cancer Specific Microbiota

The tumour environment may be characterised by a disruption to the colonic stream, a depleted mucosal barrier, altered mucin secretion, inflammation, and changes in secretory IgA release that may facilitate aberrant biofilm formation. There may also be potential changes to the intestinal substrate in the form of blood, mucins, and host-derived lactate as a glycolytic metabolic by-product. Thus, specialists within the biota could well thrive as passengers in this ecological niche. The identification of tumour-specific microbes present in mucosal and/or faecal samples, and absent in healthy controls [45–48], or tumour tissue versus the adjacent healthy mucosa [49–53], prompts investigation into their precise role in disease aetiology. Enterotoxigenic strains of *Bacteroides fragilis*, PKS⁺ strains of *Escherichia coli*, *Fusobacterium nucleatum*, *Enterococcus faecalis* and *Streptococcus gallolyticus* are candidate tumour-associated microbial species considered here for their roles in disease causality.

Streptococcus gallolyticus: Endocarditis and bacteraemia associated with *Streptococcus gallolyticus* (Sg) infection are associated with increased risk of colorectal neoplasia in observational studies [54,55]. Further, case-control studies show an increased risk of colorectal cancer associated with serological evidence of previous exposure to (Sg) antigen [56]. Faecal samples from volunteers with colorectal cancer are more likely to score positively for Sg, and tumour tissues show higher Sg counts than adjacent normal mucosa.

Experimentally, pre-exposure of cultured HCT116 cells to Sg prior to implantation resulted in the subsequent growth of a greater tumour mass in a mouse xenograft model. Further, oral gavage

with Sg increased the tumour burden in AOM and DSS mouse models of tumorigenesis [57–59]. From a mechanistic perspective, Abdulmir et al. [60] observed a higher expression of Nf-KB and IL-8 mRNA in tumour tissues from individuals seropositive for Sg antibodies versus Sg negative patients, suggesting the Sg exposure induces a pro-inflammatory state, which may be a driver of cell turnover and is thus tumour promoting. However, Kumar et al. [57] observed increased cell proliferation in cultured colon cancer cell lines (HT29, HCT116 and LoVo) exposed to Sg and demonstrated that this was driven by an increase in nuclear β -catenin independent of inflammation. Further, there is evidence to suggest that the degree of tumorigenicity of individual sub-strains of Sg is dependent upon their ability to bind to intestinal epithelial cells [61]. Thus, adherent Sg may directly stimulate epithelial cell turnover through some, as yet not fully elucidated, cellular cross-talk.

Enterococcus faecalis: *E. faecalis* is closely related to *S. gallolyticus*; it has been associated with colitis [62] and colorectal cancer in observational studies [63,64]. Mechanistically, *E. faecalis* induces colitis in experimentally susceptible animal models [65,66]; however, experiments with cultured epithelial cells suggest that it may mediate the cancer process more directly through the production of genotoxic peroxide [67] and through its influences on cell cycle behaviour and the precipitation of polyploidy [68]. Recently, Lennard et al. [63] noted the greater expression of metastasis-associated genes in *E. faecalis* positive tumour tissue compared to non-EF colonised tumours, although follow on studies are yet to confirm this potential effect.

Escherichia coli: Raisch et al. [69] studied the abundance of *E. coli* by phylogenetic subgroup in mucosal biopsies from colorectal cancer versus mucosal samples from patients with diverticular disease as a control. They reported a much higher abundance of *E. coli* from the phylogenetic subgroup B2 in the cancer patient specimens (positively identified in 73.7% of cancer specimens versus 41.9% of controls). The phylogenetic B2 subgroup is home to enteropathogenic *E. coli* strains that are frequently associated with inflammatory bowel disease [62]; Fang et al. [70] observed specialist mucin degrading metabolic apparatus amongst the B2 *E. coli*, which may contribute to their colonisation and the pathogenesis of IBD. This group may also be characterised by the presence of genes encoding cyclomodulins, and genotoxins, such as colibactin. Cycle inhibiting factor (CIF) is a cyclomodulin capable of blocking mitosis independently of DNA damage, at least in vitro [71], and of inducing apoptosis in exposed epithelial cell lines [72]. In contrast, cytotoxic necrotising factor (CNF-1) exposure precipitates a reorganisation of the actin cytoskeleton and reversible cellular senescence that may be coupled to chromosomal irregularities and genomic instability in cultured colonocytes [73].

Colibactin is a poorly characterised genotoxic polyketide-peptide produced in the gut by polyketide synthase (PKS) positive *E. coli* [74]. These PKS positive bacteria have been identified in up to 20% of healthy volunteers. In animal models of carcinogenesis, exposure to PKS may induce DNA strand breaks [75] and tumour formation [76,77]. Transient infection of cultured epithelial cells with PKS positive *E. coli* induces chromosomal aberrations and increases the mutation frequency rate [75], in addition to influencing cell cycle behaviour [78].

Bacteroides fragilis: Perhaps up to 40% of the healthy population harbour intestinal strains of *B. fragilis* that are capable of producing a metalloproteinase enterotoxin (BFT). BFT⁺ *B. fragilis* colonisation has been associated with early neoplastic changes (adenoma and serrated polyps), but not necessarily in patients shown to have carcinoma [79,80], which might suggest a role in early carcinogenesis.

In mice, colonisation with BFT⁺ *B. fragilis* is capable of inducing Th-17-mediated colitis [81] and distal colorectal cancers in the APC^{min} mouse model in a manner dependent on IL17 mediated up-regulation of NF- κ B, as demonstrated by Chung et al. [82] who observed repressed BFT-induced tumour formation in APC^{min} IL17/IL17 mice. Further, Geis et al. [83] observed an accumulation of TReg cells in the APC^{min} mouse post-BFT colonisation, which may be the trigger for an IL17-mediated pro-carcinogenic inflammatory response.

Cultured epithelial cell models suggest alternative, or indeed complimentary, pro-carcinogenic mechanisms, the BFT toxin induces cleavage of E-Cadherin, leading to increased paracellular

permeability and the activation of β -Catenin and a subsequent increase in cell proliferation [84], and it has been associated with polyamine metabolism-associated DNA damage when applied to cultured Ht29 and T80 cells [85]

It is also feasible that BFT⁺ *B. fragilis* facilitates localised microbial dysbiosis that indirectly facilitates carcinogenesis through the enabling of other pro-carcinogenic bacteria, both through its effects on the host immune apparatus [83] and potentially also through its effect on the gut barrier [84] and its recently reported influence on Muc2 synthesis and its well established role in mucin degradation [86]. Indeed, Dejea et al. [87] recently observed an abundance of biofilms co-colonised with BFT⁺ *B. fragilis* and PKS⁺ *E. coli* amongst FAP patients relative to healthy controls. They went on to demonstrate increased tumour lethality in co-colonised AOM-induced mice. Elsewhere, Drewes et al. [88] identified polymicrobial biofilms enriched with BFT⁺ *B. fragilis* and *Fusobacterium nucleatum* in 38 of 40 right-sided colorectal tumours but only 14 of 51 left-sided tumours. Tomkovich et al. [89] demonstrated that inoculation of APC min IL10^{-/-} mice with polymicrobial biofilms isolated from tumour specimens induced tumours in the mice, importantly the BFT⁺ polymicrobial biofilms were more likely to induce inflammation in the mouse distal colon than BFT⁻ samples. Interestingly, they also showed that a minority of healthy volunteers harboured colonic biofilms capable of inducing tumours in this model. This may have clinical implications for a faecal transplant, and further, given that we have limited direct proof of cancer causation, this group might warrant monitoring for future risk of colorectal cancer, and be leveraged for study in polyp recurrence studies.

Fusobacterium nucleatum is an oral symbiont, and occasional pathogen that has been identified in, and cultured from, intestinal tumours [50,90–93]. Yachida et al. [21] observed a progressive increase in the prevalence of *F. nucleatum* through the cancer stages beginning with highly dysplastic adenomas, whilst Amitay et al. [94] were unable to identify *F. nucleatum* in pre-neoplastic adenomas, suggesting that *F. nucleatum* is not a tumour initiator, but rather, an opportunistic coloniser during disease progression. Moreover, evidence suggests that *F. nucleatum* may be particularly associated with MSI and CIMP positive tumours [95]. Importantly, colonisation with FN has been associated with shorter survival in cancer patients in five out of 10 studies, as reviewed eloquently by Liu et al. [96], whilst in cultured cells, Rubinstein et al. [93] observed that *F. nucleatum* stimulates the proliferation of a panel of transformed colorectal cancer cell lines but not the non-cancerous (HEK293) cell line. In APC^{min/+} mice, inoculation with *F. nucleatum* induced the growth of significantly more tumours than in controls, whilst pre-treatment of tumour cells with *F. nucleatum* also induced significantly more tumours in a xenograft model [97]. Thus, in mice, *F. nucleatum* acts as a tumour promoter or enabler. A variety of potential tumour promoting mechanisms are being investigated. Tomkovich et al. [76,98] noted no increase in inflammation, in tumour susceptible APC^{Min/+;IL10^{-/-}} and APC^{Min/+} germ-free animals colonised with *F. nucleatum*, suggesting that *F. nucleatum* does not promote tumourigenesis via inflammation-related pathways. Evidence is instead pointing to direct E-cadherin-mediated interactions with the epithelial cell *wnt* signalling pathway, thus promoting cell proliferation [93,97,99], and through suppression of immune surveillance [92,100,101].

6. Conclusions

Candidate tumour-associated microbes are still being identified. Here, we focused on those microbes best characterised in relation to CRC. These microbes are useful in that they demonstrate various roles for gut bacteria in different carcinogenic pathways across inflammation, immune suppression and through direct modulation of host cell behaviour. The proof of cancer causality for each of these microbes, in man, remains indirect; strong mechanistic studies are emerging to explain the observational associations with disease, as are studies showing causation in animal models (Table 1). Characterisation of banked stool samples from prospective cohort studies would strengthen the current evidence base further.

Table 1. Mechanistic evidence underpinning the putative role of tumour-associated gut bacteria in colorectal carcinogenesis. + suggestive evidence, ++ multiple strands of evidence.

| | IBD Associated | Immuno- Suppressive | Pro- Inflammatory | CHROMOSOMAL instability | MSI Associated | CIMP Associated | DNA Damage Induction in Cultured Colonocytes | Proliferation Influence over Cultured Colonocytes | Metastasis Influencing |
|---|-------------------|------------------------|----------------------|----------------------------|-------------------|--------------------|---|--|---------------------------|
| <i>Streptococcus gallolyticus</i> | | | ++ | | | | | ++ | |
| <i>Enterococcus faecalis</i> | ++ | | ++ | ++ | | | ++ | ++ | + |
| CIF +ve <i>Escherichia coli</i> | ++ | | | | | | | ++ | |
| CNF +ve <i>Escherichia coli</i> | | | | + | | | | ++ | |
| Colibactin +ve <i>Escherichia coli</i> | ++ | | | | | | ++ | ++ | |
| BFT+ve <i>Bacteroides fragilis</i> | ++ | | ++ | | | | ++ | ++ | |
| <i>Fusobacterium nucleatum</i> | | ++ | | | ++ | ++ | | ++ | |

Questions also persist about the role of these tumour-associated microbes in different subtypes of CRC; *F. nucleatum*, for example, maybe more strongly associated with serrated adenomas [102,103], and BFT⁺ biofilms appear to dominate in right-sided tumours [88]. These observations may be a consequence of the wider gradient in microbial metabolic activity through the colon favouring certain bacteria in the caecum; alternatively, it may be a reflection of higher toxic concentrations in the sigmoid colon favouring the chemically-induced mutations classically associated with the adenocarcinoma sequence. Future interventions aimed at modulating gut microbial metabolism in relation to CRC risk in man might also take into account differential drivers for specific tumour type and location. Important questions also remain about the role of specific microbiota at different stages of the cancer process.

In the future, targeted removal of early-stage carcinogenic members of the gut microbial community, perhaps with phage or other approaches, might be a desirable approach to reducing risk factors for cancer. Early-stage CRC-associated bacteria might also be useful as biomarkers of disease risk. On the other hand, transient colonisers, contributing later in the carcinogenic process, might be important drug targets, or where they are favourably adherent to tumour tissue they may have the potential for leverage as drug delivery vehicles.

Author Contributions: Conceptualisation, D.M.C., G.E.W.; writing—review and editing, D.M.C., G.E.W.; writing—original draft preparation, E.A.A.

Funding: This work was funded as part of a PhD scholarship from the Government of the Sultanate of Oman.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Wiseman, M. The second World Cancer Research Fund/American Institute for Cancer Research expert report. Food, nutrition, physical activity, and the prevention of cancer: A global perspective. *Proc. Nutr. Soc.* **2008**, *67*, 253–256. [[CrossRef](#)] [[PubMed](#)]
2. Ferlay, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D.M.; Forman, D.; Bray, F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. *Int. J. Cancer* **2015**, *136*, 359–386. [[CrossRef](#)] [[PubMed](#)]
3. Kim, S.C.; Tonkonogy, S.L.; Karrasch, T.; Jobin, C.; Sartor, R.B. Dual-association of gnotobiotic IL-10^{-/-} mice with 2 nonpathogenic commensal bacteria induces aggressive pancolitis. *Inflamm. Bowel Dis.* **2007**, *13*, 1457–1466. [[CrossRef](#)] [[PubMed](#)]
4. Neumann, P.A.; Koch, S.; Hilgarth, R.S.; Perez-Chanona, E.; Denning, P.; Jobin, C.; Nusrat, A. Gut commensal bacteria and regional Wnt gene expression in the proximal versus distal colon. *Am. J. Pathol* **2014**, *184*, 592–599. [[CrossRef](#)]
5. Gustafsson, B.E. The physiological importance of the colonic microflora. *Scand. J. Gastroenterol Suppl* **1982**, *77*, 117–131.
6. Horie, H.; Kanazawa, K.; Okada, M.; Narushima, S.; Itoh, K.; Terada, A. Effects of intestinal bacteria on the development of colonic neoplasm: An experimental study. *Eur. J. Cancer Prev.* **1999**, *8*, 237–245. [[CrossRef](#)]
7. Trock, B.; Lanza, E.; Greenwald, P. Dietary fiber, vegetables, and colon cancer: Critical review and meta-analyses of the epidemiologic evidence. *J. Natl. Cancer Inst.* **1990**, *82*, 650–661. [[CrossRef](#)]
8. Aune, D.; Chan, D.S.; Lau, R.; Vieira, R.; Greenwood, D.C.; Kampman, E.; Norat, T. Dietary fibre, whole grains, and risk of colorectal cancer: Systematic review and dose-response meta-analysis of prospective studies. *BMJ* **2011**, *343*, d6617. [[CrossRef](#)]
9. Hajishafiee, M.; Saneei, P.; Benisi-Kohansal, S.; Esmailzadeh, A. Cereal fibre intake and risk of mortality from all causes, CVD, cancer and inflammatory diseases: A systematic review and meta-analysis of prospective cohort studies. *Br. J. Nutr.* **2016**, *116*, 343–352. [[CrossRef](#)]
10. Bevins, C.L.; Salzman, N.H. Paneth cells, antimicrobial peptides and maintenance of intestinal homeostasis. *Nat. Rev. Microbiol.* **2011**, *9*, 356–368. [[CrossRef](#)]
11. Irrazabal, T.; Belcheva, A.; Girardin, S.E.; Martin, A.; Philpott, D.J. The multifaceted role of the intestinal microbiota in colon cancer. *Mol. Cell* **2014**, *54*, 309–320. [[CrossRef](#)] [[PubMed](#)]

12. Tuddenham, S.; Sears, C.L. The Intestinal Microbiome and Health. *Curr. Opin. Infect. Dis.* **2015**, *28*, 464–470. [[CrossRef](#)] [[PubMed](#)]
13. Murphy, N.; Achaintre, D.; Zamora-Ros, R.; Jenab, M.; Boutron-Ruault, M.C.; Carbonnel, F.; Savoye, I.; Kaaks, R.; Kuhn, T.; Boeing, H.; et al. A prospective evaluation of plasma polyphenol levels and colon cancer risk. *Int. J. Cancer* **2018**, *143*, 1620–1631. [[CrossRef](#)] [[PubMed](#)]
14. Decroos, K.; Eeckhaut, E.; Possemiers, S.; Verstraete, W. Administration of equol-producing bacteria alters the equol production status in the Simulator of the Gastrointestinal Microbial Ecosystem (SHIME). *J. Nutr.* **2006**, *136*, 946–952. [[CrossRef](#)]
15. Fakhri, B.; Lim, K.-H. Molecular landscape and sub-classification of gastrointestinal cancers: A review of literature. *J. Gastrointest. Oncol.* **2016**, *8*, 379–386. [[CrossRef](#)]
16. Müller, M.F.; Ibrahim, A.E.K.; Arends, M.J. Molecular pathological classification of colorectal cancer. *Virchows Arch.* **2016**, *469*, 125–134. [[CrossRef](#)]
17. Gervaz, P.; Bucher, P.; Morel, P. Two colons-two cancers: Paradigm shift and clinical implications. *J. Surg. Oncol.* **2004**, *88*, 261–266. [[CrossRef](#)]
18. Ouwehand, A.C.; Derrien, M.; de Vos, W.; Tiihonen, K.; Rautonen, N. Prebiotics and other microbial substrates for gut functionality. *Curr. Opin. Biotechnol.* **2005**, *16*, 212–217. [[CrossRef](#)]
19. Gibson, G.R.; Roberfroid, M.B. Dietary modulation of the human colonic microbiota: Introducing the concept of prebiotics. *J. Nutr.* **1995**, *125*, 1401–1412. [[CrossRef](#)]
20. Liu, Y.; Gibson, G.R.; Walton, G.E. An In Vitro Approach to Study Effects of Prebiotics and Probiotics on the Faecal Microbiota and Selected Immune Parameters Relevant to the Elderly. *PLoS ONE* **2016**, *11*, e0162604. [[CrossRef](#)]
21. Yachida, S.; Mizutani, S.; Shiroma, H.; Shiba, S.; Nakajima, T.; Sakamoto, T.; Watanabe, H.; Masuda, K.; Nishimoto, Y.; Kubo, M.; et al. Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer. *Nat. Med.* **2019**, *25*, 968–976. [[CrossRef](#)] [[PubMed](#)]
22. Cummings, J.H.; Englyst, H.N. Fermentation in the human large intestine and the available substrates. *Am. J. Clin. Nutr.* **1987**, *45*, 1243–1255. [[CrossRef](#)] [[PubMed](#)]
23. Gibson, J.A.; Sladen, G.E.; Dawson, A.M. Protein absorption and ammonia production: The effects of dietary protein and removal of the colon. *Br. J. Nutr.* **1976**, *35*, 61–65. [[CrossRef](#)] [[PubMed](#)]
24. Zeng, H.; Lazarova, D.L.; Bordonaro, M. Mechanisms linking dietary fiber, gut microbiota and colon cancer prevention. *World J. Gastrointest. Oncol.* **2014**, *6*, 41–51. [[CrossRef](#)]
25. Verbeke, K.A.; Boobis, A.R.; Chiodini, A.; Edwards, C.A.; Franck, A.; Kleerebezem, M.; Nauta, A.; Raes, J.; van Tol, E.A.F.; Tuohy, K.M.; et al. Towards microbial fermentation metabolites as markers for health benefits of prebiotics. *Nutr. Res. Rev.* **2015**, *28*, 42–66. [[CrossRef](#)]
26. Hughes, R.; Magee, E.A.; Bingham, S. Protein degradation in the large intestine: Relevance to colorectal cancer. *Curr. Issues Intest. Microbiol.* **2000**, *1*, 51–58.
27. Blachier, F.; Mariotti, F.; Huneau, J.F.; Tome, D. Effects of amino acid-derived luminal metabolites on the colonic epithelium and physiopathological consequences. *Amino Acids* **2007**, *33*, 547–562. [[CrossRef](#)]
28. Peck, H.D., Jr. Enzymatic basis for assimilatory and dissimilatory sulfate reduction. *J. Bacteriol.* **1961**, *82*, 933–939.
29. Wang, R. Two's company, three's a crowd: Can H₂S be the third endogenous gaseous transmitter? *Faseb J.* **2002**, *16*, 1792–1798. [[CrossRef](#)]
30. Scanlan, P.D.; Shanahan, F.; Marchesi, J.R. Culture-independent analysis of desulfovibrios in the human distal colon of healthy, colorectal cancer and polypectomized individuals. *FEMS Microbiol. Ecol.* **2009**, *69*, 213–221. [[CrossRef](#)]
31. Roediger, W.E.; Duncan, A.; Kapaniris, O.; Millard, S. Sulphide impairment of substrate oxidation in rat colonocytes: A biochemical basis for ulcerative colitis? *Clin. Sci. (Lond.)* **1993**, *85*, 623–627. [[CrossRef](#)] [[PubMed](#)]
32. Moore, J.W.; Millard, S.; Babidge, W.; Rowland, R.; Roediger, W.E. Hydrogen sulphide produces diminished fatty acid oxidation in the rat colon in vivo: Implications for ulcerative colitis. *Aust. N. Z. J. Surg.* **1997**, *67*, 245–249. [[CrossRef](#)] [[PubMed](#)]
33. Christl, S.U.; Eisner, H.D.; Dusel, G.; Kasper, H.; Scheppach, W. Antagonistic effects of sulfide and butyrate on proliferation of colonic mucosa: A potential role for these agents in the pathogenesis of ulcerative colitis. *Dig. Dis. Sci.* **1996**, *41*, 2477–2481. [[CrossRef](#)] [[PubMed](#)]

34. Attene-Ramos, M.S.; Nava, G.M.; Muellner, M.G.; Wagner, E.D.; Plewa, M.J.; Gaskins, H.R. DNA damage and toxicogenomic analyses of hydrogen sulfide in human intestinal epithelial FHs 74 Int cells. *Environ. Mol. Mutagenesis* **2010**, *51*, 304–314. [[CrossRef](#)] [[PubMed](#)]
35. Magee, E.A.; Richardson, C.J.; Hughes, R.; Cummings, J.H. Contribution of dietary protein to sulfide production in the large intestine: An in vitro and a controlled feeding study in humans. *Am. J. Clin. Nutr.* **2000**, *72*, 1488–1494. [[CrossRef](#)] [[PubMed](#)]
36. Gibson, G.R.; Macfarlane, G.T.; Cummings, J.H. Occurrence of sulphate-reducing bacteria in human faeces and the relationship of dissimilatory sulphate reduction to methanogenesis in the large gut. *J. Appl. Bacteriol.* **1988**, *65*, 103–111. [[CrossRef](#)] [[PubMed](#)]
37. Wang, R.; Szabo, C.; Ichinose, F.; Ahmed, A.; Whiteman, M.; Papapetropoulos, A. The role of H(2)S bioavailability in endothelial dysfunction. *Trends Pharmacol. Sci.* **2015**, *36*, 568–578. [[CrossRef](#)]
38. Mu, C.; Yang, Y.; Luo, Z.; Guan, L.; Zhu, W. The Colonic Microbiome and Epithelial Transcriptome Are Altered in Rats Fed a High-Protein Diet Compared with a Normal-Protein Diet. *J. Nutr.* **2016**, *146*, 474–483. [[CrossRef](#)]
39. Hamer, H.M.; De Preter, V.; Windey, K.; Verbeke, K. Functional analysis of colonic bacterial metabolism: Relevant to health? *Am. J. Physiol. Gastrointest. Liver Physiol.* **2012**, *302*, G1–G9. [[CrossRef](#)]
40. Nowak, A.; Libudzisz, Z. Influence of phenol, p-cresol and indole on growth and survival of intestinal lactic acid bacteria. *Anaerobe* **2006**, *12*, 80–84. [[CrossRef](#)]
41. Al Hinai, E.A.; Kullamethee, P.; Rowland, I.R.; Swann, J.; Walton, G.E.; Commane, D.M. Modelling the role of microbial p-cresol in colorectal genotoxicity. *Gut Microbes* **2019**, *10*, 398–411. [[CrossRef](#)] [[PubMed](#)]
42. Tak, K.-H.; Ahn, E.; Kim, E. Increase in dietary protein content exacerbates colonic inflammation and tumorigenesis in azoxymethane-induced mouse colon carcinogenesis. *Nutr. Res. Pract.* **2017**, *11*, 281–289. [[CrossRef](#)] [[PubMed](#)]
43. Windey, K.; De Preter, V.; Louat, T.; Schuit, F.; Herman, J.; Vansant, G.; Verbeke, K. Modulation of protein fermentation does not affect fecal water toxicity: A randomized cross-over study in healthy subjects. *PLoS ONE* **2012**, *7*, e52387. [[CrossRef](#)] [[PubMed](#)]
44. Beaumont, M.; Portune, K.J.; Steuer, N.; Lan, A.; Cerrudo, V.; Audebert, M.; Dumont, F.; Mancano, G.; Khodorova, N.; Andriamihaja, M.; et al. Quantity and source of dietary protein influence metabolite production by gut microbiota and rectal mucosa gene expression: A randomized, parallel, double-blind trial in overweight humans. *Am. J. Clin. Nutr.* **2017**, *106*, 1005–1019. [[CrossRef](#)] [[PubMed](#)]
45. Wang, T.; Cai, G.; Qiu, Y.; Fei, N.; Zhang, M.; Pang, X.; Jia, W.; Cai, S.; Zhao, L. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. *ISME J.* **2012**, *6*, 320–329. [[CrossRef](#)] [[PubMed](#)]
46. Peters, B.A.; Dominianni, C.; Shapiro, J.A.; Church, T.R.; Wu, J.; Miller, G.; Yuen, E.; Freiman, H.; Lustbader, I.; Salik, J.; et al. The gut microbiota in conventional and serrated precursors of colorectal cancer. *Microbiome* **2016**, *4*, 69. [[CrossRef](#)] [[PubMed](#)]
47. Shanan, S.; Gumaa, S.A.; Sandström, G.; Abd, H. Significant Association of Streptococcus bovis with Malignant Gastrointestinal Diseases. *Int. J. Microbiol.* **2011**, *2011*, 792019. [[CrossRef](#)] [[PubMed](#)]
48. Kasai, C.; Sugimoto, K.; Moritani, I.; Tanaka, J.; Oya, Y.; Inoue, H.; Tameda, M.; Shiraki, K.; Ito, M.; Takei, Y.; et al. Comparison of human gut microbiota in control subjects and patients with colorectal carcinoma in adenoma: Terminal restriction fragment length polymorphism and next-generation sequencing analyses. *Oncol. Rep.* **2016**, *35*, 325–333. [[CrossRef](#)]
49. Chen, W.; Liu, F.; Ling, Z.; Tong, X.; Xiang, C. Human Intestinal Lumen and Mucosa-Associated Microbiota in Patients with Colorectal Cancer. *PLoS ONE* **2012**, *7*, e39743. [[CrossRef](#)]
50. Kostic, A.D.; Gevers, D.; Pédamallu, C.S.; Michaud, M.; Duke, F.; Earl, A.M.; Ojesina, A.I.; Jung, J.; Bass, A.J.; Tabernero, J.; et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. *Genome Res.* **2012**, *22*, 292–298. [[CrossRef](#)]
51. Abdulmir, A.S.; Hafidh, R.R.; Bakar, F.A. Molecular detection, quantification, and isolation of Streptococcus gallolyticus bacteria colonizing colorectal tumors: Inflammation-driven potential of carcinogenesis via IL-1, COX-2, and IL-8. *Mol. Cancer* **2010**, *9*, 249. [[CrossRef](#)] [[PubMed](#)]
52. Marchesi, J.R.; Dutilh, B.E.; Hall, N.; Peters, W.H.; Roelofs, R.; Boleij, A.; Tjalsma, H. Towards the human colorectal cancer microbiome. *PLoS ONE* **2011**, *6*, e20447. [[CrossRef](#)] [[PubMed](#)]

53. Gao, Z.; Guo, B.; Gao, R.; Zhu, Q.; Qin, H. Microbiota disbiosis is associated with colorectal cancer. *Front. Microbiol.* **2015**, *6*, 20. [[CrossRef](#)] [[PubMed](#)]
54. Gupta, A.; Madani, R.; Mukhtar, H. Streptococcus bovis endocarditis, a silent sign for colonic tumour. *Colorectal Dis. Off. J. Assoc. Coloproctology Great Br. Irel.* **2010**, *12*, 164–171.
55. Zarkin, B.A.; Lillemo, K.D.; Cameron, J.L.; Effron, P.N.; Magnuson, T.H.; Pitt, H.A. The triad of Streptococcus bovis bacteremia, colonic pathology, and liver disease. *Ann. Surg.* **1990**, *211*, 786–791, discussion 791–2. [[CrossRef](#)] [[PubMed](#)]
56. Butt, J.; Romero-Hernandez, B.; Perez-Gomez, B.; Willhauck-Fleckenstein, M.; Holzinger, D.; Martin, V.; Moreno, V.; Linares, C.; Dierssen-Sotos, T.; Barricarte, A.; et al. Association of Streptococcus gallolyticus subspecies gallolyticus with colorectal cancer: Serological evidence. *Int. J. Cancer* **2016**, *138*, 1670–1679. [[CrossRef](#)] [[PubMed](#)]
57. Kumar, R.; Herold, J.L.; Schady, D.; Davis, J.; Kopetz, S.; Martinez-Moczygemba, M.; Murray, B.E.; Han, F.; Li, Y.; Callaway, E.; et al. Streptococcus gallolyticus subsp. gallolyticus promotes colorectal tumor development. *PLoS Pathog.* **2017**, *13*, e1006440. [[CrossRef](#)]
58. McIntyre, R.E.; Buczacki, S.J.A.; Arends, M.J.; Adams, D.J. Mouse models of colorectal cancer as preclinical models. *Bioessays* **2015**, *37*, 909–920. [[CrossRef](#)]
59. Zhang, Y.; Weng, Y.; Gan, H.; Zhao, X.; Zhi, F. Streptococcus gallolyticus conspires myeloid cells to promote tumorigenesis of inflammatory bowel disease. *Biochem. Biophys. Res. Commun.* **2018**, *506*, 907–911. [[CrossRef](#)]
60. Abdulmir, A.S.; Hafidh, R.R.; Mahdi, L.K.; Al-jeboori, T.; Abubaker, F. Investigation into the controversial association of Streptococcus gallolyticus with colorectal cancer and adenoma. *BMC Cancer* **2009**, *9*, 403. [[CrossRef](#)]
61. Kumar, R.; Herold, J.L.; Taylor, J.; Xu, J.; Xu, Y. Variations among Streptococcus gallolyticus subsp. gallolyticus strains in connection with colorectal cancer. *Sci. Rep.* **2018**, *8*, 1514. [[CrossRef](#)]
62. Roche-Lima, A.; Carrasquillo-Carrion, K.; Gomez-Moreno, R.; Cruz, J.M.; Velazquez-Morales, D.M.; Rogozin, I.B.; Baerga-Ortiz, A. The Presence of Genotoxic and/or Pro-inflammatory Bacterial Genes in Gut Metagenomic Databases and Their Possible Link With Inflammatory Bowel Diseases. *Front. Genet.* **2018**, *9*, 116. [[CrossRef](#)] [[PubMed](#)]
63. Lennard, K.S.; Goosen, R.W.; Blackburn, J.M. Bacterially-Associated Transcriptional Remodelling in a Distinct Genomic Subtype of Colorectal Cancer Provides a Plausible Molecular Basis for Disease Development. *PLoS ONE* **2016**, *11*, e0166282. [[CrossRef](#)]
64. Balamurugan, R.; Rajendiran, E.; George, S.; Samuel, G.V.; Ramakrishna, B.S. Real-time polymerase chain reaction quantification of specific butyrate-producing bacteria, Desulfovibrio and Enterococcus faecalis in the feces of patients with colorectal cancer. *J. Gastroenterol. Hepatol.* **2008**, *23*, 1298–1303. [[CrossRef](#)] [[PubMed](#)]
65. Fan, T.J.; Goeser, L.; Naziripour, A.; Redinbo, M.R.; Hansen, J.J. Enterococcus faecalis Gluconate Phosphotransferase System Accelerates Experimental Colitis and Bacterial Killing by Macrophages. *Infect. Immun.* **2019**, *87*, e00080-19. [[CrossRef](#)] [[PubMed](#)]
66. Yang, Y.; Wang, X.; Huycke, T.; Moore, D.R.; Lightfoot, S.A.; Huycke, M.M. Colon Macrophages Polarized by Commensal Bacteria Cause Colitis and Cancer through the Bystander Effect. *Transl. Oncol.* **2013**, *6*, 596–606. [[CrossRef](#)]
67. Huycke, M.M.; Abrams, V.; Moore, D.R. Enterococcus faecalis produces extracellular superoxide and hydrogen peroxide that damages colonic epithelial cell DNA. *Carcinogenesis* **2002**, *23*, 529–536. [[CrossRef](#)]
68. Wang, X.; Allen, T.D.; May, R.J.; Lightfoot, S.; Houchen, C.W.; Huycke, M.M. Enterococcus faecalis induces aneuploidy and tetraploidy in colonic epithelial cells through a bystander effect. *Cancer Res.* **2008**, *68*, 9909–9917. [[CrossRef](#)] [[PubMed](#)]
69. Raisch, J.; Buc, E.; Bonnet, M.; Sauvanet, P.; Vazeille, E.; de Vallée, A.; Déchelotte, P.; Darcha, C.; Pezet, D.; Bonnet, R.; et al. Colon cancer-associated B2 Escherichia coli colonize gut mucosa and promote cell proliferation. *World J. Gastroenterol. WJG* **2017**, *20*, 6560–6572. [[CrossRef](#)]
70. Fang, X.; Monk, J.M.; Mih, N.; Du, B.; Sastry, A.V.; Kavvas, E.; Seif, Y.; Smarr, L.; Palsson, B.O. Escherichia coli B2 strains prevalent in inflammatory bowel disease patients have distinct metabolic capabilities that enable colonization of intestinal mucosa. *BMC Syst. Biol.* **2018**, *12*, 66. [[CrossRef](#)]
71. Taieb, F.; Nougayrède, J.-P.; Oswald, E. Cycle Inhibiting Factors (Cifs): Cyclomodulins That Usurp the Ubiquitin-Dependent Degradation Pathway of Host Cells. *Toxins* **2011**, *3*, 356–368. [[CrossRef](#)]

72. Samba-Louaka, A.; Nougayrede, J.P.; Watrin, C.; Oswald, E.; Taieb, F. The enteropathogenic *Escherichia coli* effector Cif induces delayed apoptosis in epithelial cells. *Infect. Immun.* **2009**, *77*, 5471–5477. [[CrossRef](#)] [[PubMed](#)]
73. Zhang, Z.; Aung, K.M.; Uhlin, B.E.; Wai, S.N. Reversible senescence of human colon cancer cells after blockage of mitosis/cytokinesis caused by the CNF1 cyclomodulin from *Escherichia coli*. *Sci. Rep.* **2018**, *8*, 17780. [[CrossRef](#)]
74. Nowrouzian, F.L.; Oswald, E. *Escherichia coli* strains with the capacity for long-term persistence in the bowel microbiota carry the potentially genotoxic pks island. *Microb. Pathog.* **2012**, *53*, 180–182. [[CrossRef](#)] [[PubMed](#)]
75. Cuevas-Ramos, G.; Petit, C.R.; Marcq, I.; Boury, M.; Oswald, E.; Nougayrede, J.P. *Escherichia coli* induces DNA damage in vivo and triggers genomic instability in mammalian cells. *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 11537–11542. [[CrossRef](#)]
76. Tomkovich, S.; Yang, Y.; Winglee, K.; Gauthier, J.; Muhlbauer, M.; Sun, X.; Mohamadzaheh, M.; Liu, X.; Martin, P.; Wang, G.P.; et al. Locoregional Effects of Microbiota in a Preclinical Model of Colon Carcinogenesis. *Cancer Res.* **2017**, *77*, 2620–2632. [[CrossRef](#)] [[PubMed](#)]
77. Arthur, J.C.; Perez-Chanona, E.; Muhlbauer, M.; Tomkovich, S.; Uronis, J.M.; Fan, T.J.; Campbell, B.J.; Abujamel, T.; Dogan, B.; Rogers, A.B.; et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. *Science* **2012**, *338*, 120–123. [[CrossRef](#)]
78. Secher, T.; Samba-Louaka, A.; Oswald, E.; Nougayrede, J.P. *Escherichia coli* producing colibactin triggers premature and transmissible senescence in mammalian cells. *PLoS ONE* **2013**, *8*, e77157. [[CrossRef](#)] [[PubMed](#)]
79. Rezasoltani, S.; Asadzadeh Aghdaei, H.; Dabiri, H.; Akhavan Sepahi, A.; Modarressi, M.H.; Nazemalhosseini Mojarad, E. The association between fecal microbiota and different types of colorectal polyp as precursors of colorectal cancer. *Microb. Pathog.* **2018**, *124*, 244–249. [[CrossRef](#)]
80. Purcell, R.V.; Pearson, J.; Aitchison, A.; Dixon, L.; Frizelle, F.A.; Keenan, J.I. Colonization with enterotoxigenic *Bacteroides fragilis* is associated with early-stage colorectal neoplasia. *PLoS ONE* **2017**, *12*, e0171602. [[CrossRef](#)]
81. Wu, S.; Rhee, K.J.; Albesiano, E.; Rabizadeh, S.; Wu, X.; Yen, H.R.; Huso, D.L.; Brancati, F.L.; Wick, E.; McAllister, F.; et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. *Nat. Med.* **2009**, *15*, 1016–1022. [[CrossRef](#)]
82. Chung, L.; Thiele Orberg, E.; Geis, A.L.; Chan, J.L.; Fu, K.; DeStefano Shields, C.E.; Dejea, C.M.; Fathi, P.; Chen, J.; Finard, B.B.; et al. *Bacteroides fragilis* Toxin Coordinates a Pro-carcinogenic Inflammatory Cascade via Targeting of Colonic Epithelial Cells. *Cell Host Microbe* **2018**, *23*, 203–214.e5. [[CrossRef](#)] [[PubMed](#)]
83. Geis, A.L.; Fan, H.; Wu, X.; Wu, S.; Huso, D.L.; Wolfe, J.L.; Sears, C.L.; Pardoll, D.M.; Housseau, F. Regulatory T-cell Response to Enterotoxigenic *Bacteroides fragilis* Colonization Triggers IL17-Dependent Colon Carcinogenesis. *Cancer Discov.* **2015**, *5*, 1098–1109. [[CrossRef](#)] [[PubMed](#)]
84. Wu, S.; Rhee, K.J.; Zhang, M.; Franco, A.; Sears, C.L. *Bacteroides fragilis* toxin stimulates intestinal epithelial cell shedding and gamma-secretase-dependent E-cadherin cleavage. *J. Cell Sci.* **2007**, *120*, 1944–1952. [[CrossRef](#)] [[PubMed](#)]
85. Goodwin, A.C.; Destefano Shields, C.E.; Wu, S.; Huso, D.L.; Wu, X.; Murray-Stewart, T.R.; Hacker-Prietz, A.; Rabizadeh, S.; Woster, P.M.; Sears, C.L.; et al. Polyamine catabolism contributes to enterotoxigenic *Bacteroides fragilis*-induced colon tumorigenesis. *Proc. Natl. Acad. Sci. USA* **2011**, *108*, 15354–15359. [[CrossRef](#)]
86. Allen, J.; Hao, S.; Sears, C.L.; Timp, W. Epigenetic Changes Induced by *Bacteroides fragilis* Toxin. *Infect. Immun.* **2019**, *87*. [[CrossRef](#)]
87. Dejea, C.M.; Fathi, P.; Craig, J.M.; Boleij, A.; Taddese, R.; Geis, A.L.; Wu, X.; DeStefano Shields, C.E.; Hechenbleikner, E.M.; Huso, D.L.; et al. Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. *Science* **2018**, *359*, 592–597. [[CrossRef](#)]
88. Drewes, J.L.; White, J.R.; Dejea, C.M.; Fathi, P.; Iyadorai, T.; Vadivelu, J.; Roslani, A.C.; Wick, E.C.; Mongodin, E.F.; Loke, M.F.; et al. High-resolution bacterial 16S rRNA gene profile meta-analysis and biofilm status reveal common colorectal cancer consortia. *NPJ Biofilms Microbiomes* **2017**, *3*, 34. [[CrossRef](#)]
89. Tomkovich, S.; Dejea, C.M.; Winglee, K.; Drewes, J.L.; Chung, L.; Housseau, F.; Pope, J.L.; Gauthier, J.; Sun, X.; Muhlbauer, M.; et al. Human colon mucosal biofilms from healthy or colon cancer hosts are carcinogenic. *J. Clin. Investig.* **2019**, *130*, 1699–1712. [[CrossRef](#)]

90. Castellarin, M.; Warren, R.L.; Freeman, J.D.; Dreolini, L.; Krzywinski, M.; Strauss, J.; Barnes, R.; Watson, P.; Allen-Vercoe, E.; Moore, R.A.; et al. *Fusobacterium nucleatum* infection is prevalent in human colorectal carcinoma. *Genome Res.* **2012**, *22*, 299–306. [\[CrossRef\]](#)
91. Li, Y.Y.; Ge, Q.X.; Cao, J.; Zhou, Y.J.; Du, Y.L.; Shen, B.; Wan, Y.J.; Nie, Y.Q. Association of *Fusobacterium nucleatum* infection with colorectal cancer in Chinese patients. *World J. Gastroenterol.* **2016**, *22*, 3227–3233. [\[CrossRef\]](#)
92. Kostic, A.D.; Chun, E.; Robertson, L.; Glickman, J.N.; Gallini, C.A.; Michaud, M.; Clancy, T.E.; Chung, D.C.; Lochhead, P.; Hold, G.L.; et al. *Fusobacterium nucleatum* potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. *Cell Host Microbe* **2013**, *14*, 207–215. [\[CrossRef\]](#) [\[PubMed\]](#)
93. Rubinstein, M.R.; Wang, X.; Liu, W.; Hao, Y.; Cai, G.; Han, Y.W. *Fusobacterium nucleatum* promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin. *Cell Host Microbe* **2013**, *14*, 195–206. [\[CrossRef\]](#) [\[PubMed\]](#)
94. Amitay, E.L.; Werner, S.; Vital, M.; Pieper, D.H.; Hofler, D.; Gierse, I.J.; Butt, J.; Balavarca, Y.; Cuk, K.; Brenner, H. *Fusobacterium* and colorectal cancer: Causal factor or passenger? Results from a large colorectal cancer screening study. *Carcinogenesis* **2017**, *38*, 781–788. [\[CrossRef\]](#) [\[PubMed\]](#)
95. Lee, D.W.; Han, S.W.; Kang, J.K.; Bae, J.M.; Kim, H.P.; Won, J.K.; Jeong, S.Y.; Park, K.J.; Kang, G.H.; Kim, T.Y. Association Between *Fusobacterium nucleatum*, Pathway Mutation, and Patient Prognosis in Colorectal Cancer. *Ann. Surg. Oncol.* **2018**, *25*, 3389–3395. [\[CrossRef\]](#)
96. Liu, Y.; Baba, Y.; Ishimoto, T.; Iwatsuki, M.; Hiyoshi, Y.; Miyamoto, Y.; Yoshida, N.; Wu, R.; Baba, H. Progress in characterizing the linkage between *Fusobacterium nucleatum* and gastrointestinal cancer. *J. Gastroenterol.* **2019**, *54*, 33–41. [\[CrossRef\]](#)
97. Yang, Y.; Weng, W.; Peng, J.; Hong, L.; Yang, L.; Toiyama, Y.; Gao, R.; Liu, M.; Yin, M.; Pan, C.; et al. *Fusobacterium nucleatum* Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4 Signaling to Nuclear Factor-kappaB, and Up-regulating Expression of MicroRNA-21. *Gastroenterology* **2017**, *152*, 851–866.e24. [\[CrossRef\]](#)
98. Tahara, T.; Hirata, I.; Nakano, N.; Tahara, S.; Horiguchi, N.; Kawamura, T.; Okubo, M.; Ishizuka, T.; Yamada, H.; Yoshida, D.; et al. Potential link between *Fusobacterium* enrichment and DNA methylation accumulation in the inflammatory colonic mucosa in ulcerative colitis. *Oncotarget* **2017**, *8*, 61917–61926. [\[CrossRef\]](#)
99. Chen, Y.; Peng, Y.; Yu, J.; Chen, T.; Wu, Y.; Shi, L.; Li, Q.; Wu, J.; Fu, X. Invasive *Fusobacterium nucleatum* activates beta-catenin signaling in colorectal cancer via a TLR4/P-PAK1 cascade. *Oncotarget* **2017**, *8*, 31802–31814. [\[CrossRef\]](#)
100. Ye, X.; Wang, R.; Bhattacharya, R.; Boulbes, D.R.; Fan, F.; Xia, L.; Adoni, H.; Ajami, N.J.; Wong, M.C.; Smith, D.P.; et al. *Fusobacterium Nucleatum* Subspecies *Animalis* Influences Proinflammatory Cytokine Expression and Monocyte Activation in Human Colorectal Tumors. *Cancer Prev Res. (Phila)* **2017**, *10*, 398–409. [\[CrossRef\]](#)
101. Park, H.E.; Kim, J.H. Intratumoral *Fusobacterium nucleatum* abundance correlates with macrophage infiltration and CDKN2A methylation in microsatellite-unstable colorectal carcinoma. *Virchows Arch.* **2017**, *471*, 329–336. [\[CrossRef\]](#)
102. Ito, M.; Kanno, S.; Nosho, K.; Sukawa, Y.; Mitsuhashi, K.; Kurihara, H.; Igarashi, H.; Takahashi, T.; Tachibana, M.; Takahashi, H.; et al. Association of *Fusobacterium nucleatum* with clinical and molecular features in colorectal serrated pathway. *Int. J. Cancer* **2015**, *137*, 1258–1268. [\[CrossRef\]](#) [\[PubMed\]](#)
103. Yoon, H.; Kim, N.; Park, J.H.; Kim, Y.S.; Lee, J.; Kim, H.W.; Choi, Y.J.; Shin, C.M.; Park, Y.S.; Lee, D.H.; et al. Comparisons of Gut Microbiota Among Healthy Control, Patients With Conventional Adenoma, Sessile Serrated Adenoma, and Colorectal Cancer. *J. Cancer Prev.* **2017**, *22*, 108–114. [\[CrossRef\]](#) [\[PubMed\]](#)

